# Valo Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/valo-health

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.valohealth.com
- Total disclosed funding: $403M
- Latest round: Series C (Oct 28, 2022)
- Investors on record: 8

## About

Based in Massachusetts, US, and founded in 2019, Valo Health, LLC operates as a technology company that uses human-centric data and AI to enhance the drug discovery and development process. The company was founded by David Berry. In March 2021, Valo Health, LLC received its latest Series B funding from Koch Disruptive Technologies.

Valo Health, LLC is a provider of an integrated drug development platform called Opal Computational Platform, an integrated platform that combines machine learning-driven computational capabilities and patient data to develop therapeutic programs across major disease areas.

Valo Health, LLC plans to use its funding from March 2021 for scaling the Opal Computational Platform, working capital, and other general purposes.

## Funding rounds

- Series C, Oct 28, 2022, $2.5M — HBM Partners
- Series B, Mar 9, 2021, $110M — Koch Disruptive Technologies
- Series B, Dec 16, 2020, $190M — Flagship Pioneering, HBM Partners, Public Sector Pension Investment Board, Invus [DUP], Atinum Investment, Mirae Asset Capital, Longevity Vision Holding
- Series A, Jul 1, 2019, $100M — Flagship Pioneering, Public Sector Pension Investment Board

## Investors

- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series A, Series B
- Public Sector Pension Investment Board — Series A, Series B
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series B, Series C
- Invus [DUP] — Series B
- Atinum Investment (https://capitalatlas.ai/funds/atinum-investment) — Series B
- Mirae Asset Capital (https://capitalatlas.ai/funds/mirae-asset-capital) — Series B
- Longevity Vision Holding (https://capitalatlas.ai/funds/longevity-vision-holding) — Series B
- Koch Disruptive Technologies (https://capitalatlas.ai/funds/koch-disruptive-technologies) — Series B